English

RLS GLOBAL AB (publ) PUBLISHES INTERIM REPORT FOR THE PERIOD APRIL–JUNE 2023

Report this content

RLS Global AB (publ) (“RLS”) or the “Company”) today publishes the Company’s interim report for the second quarter 2023.

APRIL 1st – JUNE 30th (Previous year in brackets)

  • Net sales amounted to TSEK 223 (TSEK 397)
  • Earnings before interest and taxes (EBIT) amounted to MSEK -7,5 (MSEK 5,8)
  • Earnings per share before dilution at SEK -0,09 (SEK 0,09)
  • Cash flow from operating activities amounted to TSEK -6 904 (TSEK -5 929)
  • Liquid assets at the end of the period MSEK 4,6 ( MSEK 5,8)
  • Equity ratio was 71 % (43 %)

 

JANUARY 1st – JUNE 30th (Previous year in brackets)

  • Net sales amounted to TSEK 312 (TSEK 705)
  • Earnings before interest and taxes (EBIT) amounted to MSEK -15,4 (MSEK -11,1)
  • Earnings per share before dilution at SEK -0,19 (SEK 0,16)
  • Cash flow from operating activities amounted to MSEK -13,9 (MSEK -12,7)
  • Liquid assets at the end of the period MSEK 4,6 (MSEK 5,8)
  • Equity ratio was 71 % (43 %)

 

Summary of events during SECOND quarter

  • AGM is held on June 30th.

 

Summary of events after SECOND quarteR

  • Björn Larsson leaves his role as CEO for RLS Global. Board member Roland Frösing is appointed interim CEO.
  • Torbjörn Sannerstedt is appointed as the company’s new CFO after Eva Jagenheim has announced that she is leaving the company.
  • RLS Global has raised a short-term loan of MSEK 5,0 from several external investors.

The Interim Report Q2, 2023, is enclosed and is also available at https://rls.global/financial-information/financial-reports-eng/
 

Publication
This information was submitted for publication through the agency of the below contact person, at 09.00 CET on Aug 25th 2023.

TRADING PLACE AND CERTIFIED ADVISER:
RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag.
 

FOR MORE INFORMATION, PLEASE CONTACT:
Roland Frösing, acting CEO, RLS Global
E-mail: roland.frosing@rlsglobal.se
Phone: +46 723 20 61 00

ABOUT RLS GLOBAL:
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS develops and sells products under the brand ChloraSolv® for indications within advanced wound care.
RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand into new indications through new research and development projects in areas such as wound care and dermatology. To maximize market presence, RLS works with partners to commercialize products globally. RLS is convinced that the company’s platform technology and its unique features will help many patients around the world. Read more at rls.global

Subscribe

Documents & Links